BCL2 and thyroid gland carcinoma: Furthermore, EVO alone or in combination with chemotherapeutic agent wortmannin could inhibit cell growth, migration, and EMT and induce apoptosis by decreasing the levels of Bcl-2, phospho-Akt, and matrix metalloproteinases-2 and -9 proteins and increasing the levels of p21 and p53 proteins in thyroid cancer TPC-1 and SW1736 cells (Kim et al., 2018).